Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Diagnostic characteristics of lethal prostate cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Measured and genetically predicted plasma YKL-40 levels and melanoma mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Prognostic factors for relapse in patients with clinical stage I testicular cancer: Protocol for a Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The diagnostic characteristics of men who eventually die from prostate cancer (PCa) and the extent to which early diagnostic strategies have affected these characteristics are unclear. We aimed to investigate trends in survival and clinical presentation at diagnosis in men who eventually died from PCa.

PATIENTS AND METHODS: Based on the national database, the Danish Prostate Cancer Registry, a nationwide population-based study of all 19,487 men who died from PCa in Denmark between 1995 and 2013 was conducted. Trends in median survival and trends in age, prostate-specific antigen (PSA), clinical stage, and Gleason score (GS) at diagnosis were analysed.

RESULTS: A total of 46.9%, 16.8%, and 36.3% had metastatic (M+), locally advanced/lymph node positive (LaN+), and localised disease, respectively, at diagnosis. Only 0.15% had localised disease, GS ≤ 6 and PSA<10. Over time, the proportion of men with M+ disease at diagnosis decreased from 54.0-38.3% (p < 0.0001), whereas the proportion LaN + disease increased from 8.6-27.3% (p < 0.0001). The proportion of localised disease remained stable at 33.2-41.9%. Median survival increased 2.11 years from 1.88 (95% CI: 1.68-2.08) in 1995 to 3.99 (95% CI: 3.71-4.28) years in 2013, p < 0.0001.

CONCLUSIONS: In a large population-based study, the results confirmed concurrent literature that the majority of men who eventually died from PCa had LaN+ or M+ disease at diagnosis. The proportion of men with M+ disease at diagnosis decreased significantly over time, parallelled by an increase in median survival. Taken together, this indicates a lead-time effect on survival, which presently, however, is not substantial enough to result in a reduced PCa-specific mortality.

Original languageEnglish
JournalEuropean journal of cancer (Oxford, England : 1990)
Volume84
Pages (from-to)18-26
Number of pages9
ISSN0959-8049
DOIs
Publication statusPublished - Oct 2017

    Research areas

  • Journal Article

ID: 51683420